219 related articles for article (PubMed ID: 15273119)
1. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.
Hegde SS; Reyes N; Wiens T; Vanasse N; Skinner R; McCullough J; Kaniga K; Pace J; Thomas R; Shaw JP; Obedencio G; Judice JK
Antimicrob Agents Chemother; 2004 Aug; 48(8):3043-50. PubMed ID: 15273119
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh model.
Hegde SS; Okusanya OO; Skinner R; Shaw JP; Obedencio G; Ambrose PG; Blais J; Bhavnani SM
Antimicrob Agents Chemother; 2012 Mar; 56(3):1578-83. PubMed ID: 22155835
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
MacGowan AP; Noel AR; Tomaselli S; Elliott HC; Bowker KE
Antimicrob Agents Chemother; 2011 Feb; 55(2):867-73. PubMed ID: 21078943
[TBL] [Abstract][Full Text] [Related]
4. Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
Laohavaleeson S; Kuti JL; Nicolau DP
Expert Opin Investig Drugs; 2007 Mar; 16(3):347-57. PubMed ID: 17302529
[TBL] [Abstract][Full Text] [Related]
5. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model.
Louie A; Liu W; Kulawy R; Drusano GL
Antimicrob Agents Chemother; 2011 Jul; 55(7):3453-60. PubMed ID: 21502615
[TBL] [Abstract][Full Text] [Related]
6. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
[TBL] [Abstract][Full Text] [Related]
7. Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus.
Lepak AJ; Zhao M; Andes DR
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416551
[TBL] [Abstract][Full Text] [Related]
8. Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus.
Leonard SN; Supple ME; Gandhi RG; Patel MD
Antimicrob Agents Chemother; 2013 Jun; 57(6):2678-83. PubMed ID: 23545527
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model.
Yin LY; Calhoun JH; Thomas TS; Wirtz ED
J Antimicrob Chemother; 2009 Feb; 63(2):357-60. PubMed ID: 19060292
[TBL] [Abstract][Full Text] [Related]
10. In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.
Hilliard JJ; Fernandez J; Melton J; Macielag MJ; Goldschmidt R; Bush K; Abbanat D
Antimicrob Agents Chemother; 2009 May; 53(5):2028-33. PubMed ID: 19273686
[TBL] [Abstract][Full Text] [Related]
11. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
Karlowsky JA; Nichol K; Zhanel GG
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S58-68. PubMed ID: 26316559
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients.
Rolston K; Wang W; Nesher L; Coyle E; Shelburne S; Prince RA
J Antibiot (Tokyo); 2014 Jul; 67(7):505-9. PubMed ID: 24824818
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.
Reyes N; Skinner R; Kaniga K; Krause KM; Shelton J; Obedencio GP; Gough A; Conner M; Hegde SS
Antimicrob Agents Chemother; 2005 Oct; 49(10):4344-6. PubMed ID: 16189117
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
Mendes RE; Moet GJ; Janechek MJ; Jones RN
Antimicrob Agents Chemother; 2010 Jun; 54(6):2704-6. PubMed ID: 20385851
[TBL] [Abstract][Full Text] [Related]
15. In vivo pharmacodynamics of a new oxazolidinone (linezolid).
Andes D; van Ogtrop ML; Peng J; Craig WA
Antimicrob Agents Chemother; 2002 Nov; 46(11):3484-9. PubMed ID: 12384354
[TBL] [Abstract][Full Text] [Related]
16. Telavancin: a new lipoglycopeptide for gram-positive infections.
Smith WJ; Drew RH
Drugs Today (Barc); 2009 Mar; 45(3):159-73. PubMed ID: 19436839
[TBL] [Abstract][Full Text] [Related]
17. In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure.
Thabit AK; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2016 Jan; 60(1):222-8. PubMed ID: 26482306
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
Crandon JL; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2010 Dec; 54(12):5115-9. PubMed ID: 20837760
[TBL] [Abstract][Full Text] [Related]
19. In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model.
Jacqueline C; Batard E; Perez L; Boutoille D; Hamel A; Caillon J; Kergueris MF; Potel G; Bugnon D
Antimicrob Agents Chemother; 2002 Dec; 46(12):3706-11. PubMed ID: 12435665
[TBL] [Abstract][Full Text] [Related]
20. Telavancin: a novel lipoglycopeptide antimicrobial agent.
Attwood RJ; LaPlante KL
Am J Health Syst Pharm; 2007 Nov; 64(22):2335-48. PubMed ID: 17989443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
